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Huntington’s disease (HD) is a fatal inherited neurodegenerative
disorder. HD is caused by polyglutamine expansions in the hun-
tingtin (htt) protein that result in neuronal loss and contribute to
HD pathology. The mechanisms of neuronal loss in HD are elusive,
and there is no therapy to alleviate HD. To find small molecules that
slow neuronal loss in HD, we screened 1,040 biologically active
molecules to identify suppressors of cell death in a neuronal cell
culture model of HD. We found that inhibitors of mitochondrial
function or glycolysis rescued cell death in this cell culture and in
in vivo HD models. These inhibitors prevented cell death by
activating prosurvival ERK and AKT signaling but without altering
cellular ATP levels. ERK and AKT inhibition through the use of
specific chemical inhibitors abrogated the rescue, whereas their
activation through the use of growth factors rescued cell death,
suggesting that this activation could explain the protective effect
of metabolic inhibitors. Both ERK and AKT signaling are disrupted
in HD, and activating these pathways is protective in several HD
models. Our results reveal a mechanism for activating prosurvival
signaling that could be exploited for treating HD and possibly
other neurodegenerative disorders.
caspase  ERK  survival signaling  drugs  neurodegeneration
Huntington’s disease (HD) is an inherited, adult onset,progressive neurodegenerative disorder (1). HD is caused
by a polyglutamine expansion (36 glutamine repeats) in the
huntingtin protein (htt) that leads to neuronal dysfunction and
death (1, 2). The mechanism(s) by which the polyglutamine
expansion in htt leads to HD pathology remain elusive. Numer-
ous mechanisms including transcriptional dysregulation, altered
intracellular trafficking, sequestration of critical cellular proteins
in aggregates, aberrant caspase activation, and altered energy
metabolism have been implicated in HD (2).
HD is a fatal disease with no therapy. To identify potential
compounds for development as drugs and to use these com-
pounds to gain mechanistic understanding of HD, we used a
screening approach to identify small molecule suppressors of cell
death in a cell culture model of HD. In this model, rat striatal
neurons that were immortalized by expression of a temperature-
sensitive large T antigen were engineered to express a mutant
N-terminal, 548-aa fragment of human htt with 120 glutamine
repeats to generate the N548 mutant cell line (3). Serum
deprivation and a change to the nonpermissive temperature
(39°C) causes T antigen degradation and N548 mutant cell death
(3). Cell death can be used as an indicator of mutant htt toxicity
because the cells expressing mutant htt die faster than parental
cells (3). By using a previously described high-throughput assay
(4), we discovered that metabolic inhibitors rescued cell death in
this cell culture model and in two in vivo HD models. These
compounds activated ERK and AKT prosurvival signaling.
Furthermore, growth-factor-induced activation of ERK and
AKT rescued cell death, thus elucidating a novel mechanism of
rescue by these metabolic inhibitors.
Results
Mitochondrial Inhibitor Rotenone Rescues Cell Death in N548 Mutant
Cells. We screened a collection of 1,040 biologically active
compounds (see Materials and Methods) by using a previously
described high-throughput screening assay (4). We identified
that rotenone, an inhibitor of complex I of the mitochondrial
electron transport chain (ETC) (5), suppressed cell death in
N548 mutant htt-expressing cells. Cell death rescue was con-
firmed by three independent cell viability assays and over a time
course of 7 days (Fig. 1 A–C). Cell death rescue was verified in
three independent clonal cell lines expressing N548 mutant htt
(data not shown). We excluded the possibility that rotenone
rescued cell death by decreasing the expression of htt transgene
or altering T antigen levels (Fig. 1D). Because mutant htt
aggregation is associated with HD (2), we tested the effects of
rotenone on htt aggregation. In this model, occasional cells
(1%) showed visible aggregation by immunofluorescence [sup-
porting information (SI) Fig. 6]. The low propensity of mutant
htt to form microscopically visible aggregates may be due to the
longer (N-terminal, 548-aa) htt fragment used in this model
compared with other models because decreased aggregation of
larger htt fragments has been reported in cell culture and in
mouse models (6, 7). The percentage of cells with aggregates was
not enhanced by rotenone, indicating that the effect on visible
aggregation is unlikely to play a role in cell death rescue by
rotenone.
Diverse Metabolic Inhibitors Rescue Cell Death. Because rotenone
inhibits mitochondrial complex I of the ETC, we expanded our
analysis and tested whether perturbing other aspects of metab-
olism would prevent cell death. We found that diverse inhibitors
of metabolism prevented cell death. The compounds tested, their
sites of action (Fig. 1E and SI Fig. 7), and their efficacy are shown
in SI Table 1. We found that inhibitors of glycolysis (sodium
fluoride), ATP synthetase (oligomycin), and mitochondrial cou-
pling 2,4-dinitrophenol (8–10) all rescued cell death. These
results indicated that mitochondrial ETC inhibition per se was
not required for the rescue.
Rotenone Rescues Neuronal Loss in Multiple in Vivo HD Models.Next,
we tested the ability of rotenone to alleviate neuronal loss and
degeneration in two invertebrate models of HD. In a Caeno-
rhabditis elegans model, an N-terminal, 171-aa fragment of
human htt with 150 glutamines is expressed in ASH sensory
neurons of polyglutamine enhancer-1 (pqe-1) genetic back-
ground animals. The pqe-1 background enhances mutant htt
toxicity and causes age-dependent ASH neuronal death within 3
days (11). ASH neuronal death is monitored by the loss of GFP
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reporter expression (Fig. 2A) (11). Rotenone caused a dramatic
and dose-dependent rescue of ASH neuronal cell death (Fig. 2B,
left graph). Because mitochondrial inhibition can slow the aging
process (12) and HD is linked to aging (13), we tested whether
the effect of rotenone on aging could be dissociated from those
on neuronal death by using an assay format in which the animals
were growth arrested in the L1 larval stage by starvation (see
Materials and Methods). Rotenone was effective in preventing
ASH neuronal death of animals under starvation (Fig. 2B, right
graph), indicating that it was effective independent of effects on
growth or development.
Next, we tested rotenone in a Drosophila HD model in which
an N-terminal, 170-aa fragment of human htt containing 120
glutamine repeats is expressed in the Drosophila eye (14). WT
Drosophila have seven visible photoreceptor subunits (rhab-
domeres) per light collecting unit (ommatidium). Expression of
mutant htt transgene causes a progressive decrease in the
number of rhabdomeres per ommatidium (Fig. 2C and SI Fig. 8).
Treatment with rotenone rescued rhabdomere loss compared
with vehicle-treated controls (Fig. 2D and SI Fig. 8). Rescue by
rotenone was similar to that by sodium butyrate (Fig. 2D), a
histone deacetylase inhibitor that is active in Drosophila and
mouse HDmodels (15, 16). A few other mitochondrial inhibitors
were also active in the C. elegans and Drosophila HD models (SI
Table 1).
Mitochondrial Inhibitors Suppress Caspase Activation. To gain in-
sight into the mechanism of cell death rescue, we assessed the
effects of mitochondrial inhibitors on the cell death machinery.
Caspases are key regulators of cell death and are involved in HD
toxicity, both as targets of mutant htt and as modulators of
mutant htt toxicity, by inducing cleavage and generation of toxic
htt fragments (17, 18). Cell death upon serum deprivation in
N548 mutant cells is largely mediated by caspase activation
because the broad-spectrum caspase inhibitor Boc-D-FMK res-
cues cell death (4). We found that both oligomycin and rotenone
inhibited the generation of two downstream effectors in the
apoptotic cascade, cleaved active caspase 3 and 7 fragments that
correlated with suppression of cell death (Fig. 3 A and B),
suggesting that this mechanism was relevant to rescue by these
inhibitors.
Alterations in ATP, NADH, and Reactive Oxygen Species Levels Are Not
Involved in Rescue. Mitochondrial inhibitors can prevent cell
death by altering cellular ATP levels (19, 20). We examined
whether this mechanism contributed to suppression of cell death
in our model. Mitochondrial inhibitors at concentrations that
resulted in maximum rescue of cell death caused no decrease in
ATP levels in N548 mutant cells (Fig. 3C). Furthermore, time
course experiments failed to show a transient decline in ATP
levels in oligomycin-treated cells relative to vehicle (DMSO)-
treated cells (Fig. 3D). The decline in ATP levels at later times
(48 h) is likely due to decreased viability because a larger decline
in ATP levels was noted in DMSO-treated cells relative to
oligomycin treated cells.
The result that cellular ATP levels did not decrease upon
treating cells with mitochondrial inhibitors was unexpected. One
explanation for this result could be that glycolysis was maintain-
ing cellular ATP levels because both glycolysis and oxidative
phosphorylation contribute to cellular ATP (SI Fig. 7). We
found that oligomycin dramatically decreased cellular ATP
levels when glycolysis was inhibited (cells grown in media
without glucose) but not when glycolysis was functional (SI Fig.
9). This result suggests that both glycolysis and mitochondrial
oxidative phosphorylation contribute to ATP production in
N548 mutant cells and that glycolysis was likely maintaining
cellular ATP levels upon mitochondrial inhibition.
Mitochondrial ETC inhibition also causes an accumulation of
NADH (21), the principal product of the citric acid cycle, and can
alter reactive oxygen species levels (21, 22). Increased NADH
levels can prevent degeneration and cell death in certain models
(21, 23). We found that neither exogenous NADH nor NAD
nor a precursor of NADH (nicotinamide) rescued cell death at
any of the concentrations tested (SI Fig. 10 and data not shown).
Furthermore, mitochondrial uncouplers and glycolysis inhibitors
rescued cell death (SI Table 1), despite the fact that they do not
cause NADH accumulation (SI Fig. 7). Together, these data
suggest that accumulation of NADH is not a relevant mechanism
of rescue. Finally, we found no changes in reactive oxygen species
levels upon treating cells with mitochondrial inhibitors, thus
excluding this mechanism of rescue (SI Fig. 10).
Metabolic Inhibitors Activate Prosurvival ERK and AKT Signaling.
Altered cell survival signaling (ERK and AKT) is implicated in
HD; components of these pathways are decreased or inhibited in
HD (24–26), and their activation is protective in HDmodels (24,
27). We tested whether these pathways were activated by met-
abolic inhibitor treatment by measuring activating phosphory-
lation of specific amino acid residues on AKT and ERK proteins
(24, 27). Rotenone treatment caused rapid and sustained acti-
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Fig. 1. Mitochondrial inhibitor rescues cell death in N548 mutant cells. (A) A
dose–response experiment showing viability of N548 mutant cells treated
with rotenone. Viability was determined by the calcein acetoxymethyl ester
assay (seeMaterials andMethods) and is expressed as fold increase relative to
DMSO-treated cells. The results are the averages  SD of an experiment
performed in triplicate. (B) Cells were incubated in serum-deprived media
(Sdm) with DMSO or rotenone (10 M), and cell viability was analyzed every
day for 7 days by the trypan blue dye-exclusion assay. The data are averages
SD from one of two independent experiments, each performed in duplicate.
(C) Photomicrographs of cells in Sdm containing DMSO or rotenone for 2 days,
as viewed by light microscopy. Dying cells detach, round up, and are brighter
than attached cells. (D) Expression of mutant htt and T antigen assayed by
Western blotting in cells treated with DMSO (D) or rotenone (Rot) for 12 h in
Sdm at 39°C or in serum-containing media (Ser) at 33°C. 1C2 antibody detects
expanded polyglutamine containing htt, and MAB2166 detects both WT and
mutant htt. The temperature-sensitive T antigen is stable at 33°C and de-
grades at 39°C. Tubulin was the loading control. (E) Glucose metabolism
pathway and sites of action of the diverse metabolic inhibitors used in this
study (indicated by red bars). For details, see SI Fig. 7.
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vation of AKT and ERK (Fig. 4A). The activation of ERK/AKT
was specific because several distinct kinase pathways: JAK2,
NF-B, p38 MAPK, and glycogen synthase kinase-3 / path-
ways were not activated by rotenone treatment (Fig. 4B). The
activation of ERK/AKT was dose dependent and correlated with
rescue of cell death (Figs. 4C and 1A), suggesting that this
activation contributed to the rescue of cell death. We also
confirmed activation of these pathways by rotenone in two
additional clones of N548 mutant cells (Fig. 4D). This activation
was not observed in cells treated with vehicle control (DMSO),
confirming that it was not an indirect effect of serum starvation
(Fig. 4 A–D). Furthermore, the pan-caspase inhibitor Boc-D-
FMK (28) suppressed cell death of N548 mutant cells (4) but
failed to activate these pathways (Fig. 4E), indicating that ERK
and AKT activation was not an indirect effect of cell survival.
Similar activation of ERK was observed by using the glycolysis
inhibitor sodium fluoride (NaF) and the mitochondrial ATP
synthetase inhibitor oligomycin, indicating that this activation
was not an off-target effect of rotenone treatment (SI Fig. 11).
ERK/AKT Activation by Rotenone Is Independent of Mitochondrial
Respiration.Our results indicated that a decrease in total cellular
ATP levels was not responsible for activating prosurvival sig-
naling or the protection by rotenone. However, because cellular
ATP levels are dependent on both glycolysis and oxidative
phosphorylation, it was possible that inhibiting mitochondrial
ATP production triggered ERK/AKT activation. To test this
possibility, we generated two mitochondrial DNA-deficient (0)
N548 mutant cell lines by using established protocols (29). In 0
cells, mitochondrial DNA-encoded subunits of ETC complexes
are not generated, making these cells deficient in ATP produc-
tion by oxidative phosphorylation (30). Rotenone activated ERK
and AKT and also rescued cell death in 0 cells to a similar extent
as that in the parental N548 mutant cells (SI Fig. 12). These
results indicate that decreased mitochondrial ATP production
upon rotenone treatment is unlikely to cause rescue of cell death
or to activate ERK and AKT.
ERK and AKT Activation Partially Explains Rescue by Metabolic Inhib-
itors. If activation of ERK and AKT by rotenone is important for
rescue, then inhibiting their activation should abrogate the
rescue by mitochondrial inhibitors, and, conversely, activating
them should rescue cell death. We found that AKT and ERK
inhibition by using specific chemical inhibitors of ERK and AKT
abrogated the rescue by rotenone in a dose-dependent manner
(SI Fig. 13). Moreover, the IC50 of abrogation of rescue by
rotenone by these chemical inhibitors was similar to their
reported cellular IC50 for the respective kinases (see Materials
























































































Fig. 2. Rotenone rescues neuronal loss in two in vivo HD models. (A) A GFP reporter was coexpressed with mutant htt in the ASH neurons of C. elegans and
was used to assess neuronal cell viability in vivo. Live neurons express GFP (arrow), and loss of GFP expression indicates cell death. (B) Rescue of age-dependent
ASH neuronal death by rotenone (Rot). Animals were treated with DMSO (vehicle) or rotenone in the presence of food (left graph) or under starvation conditions
(right graph). ASH neuronal viability was assayed in live animals at the time indicated. One hundred neurons (50 animals) were counted per treatment per time
point, and the data are representative of two independent experiments. (C) Mutant htt expression in the photoreceptors of Drosophila results in a
time-dependent degeneration. WT animals have seven visible-light-collecting units (rhabdomeres) per ommatidium when viewed by light microscopy. Mutant
htt-expressing animals (Mut) show a decrease in the number of rhabdomeres at day 1 after eclosion (emergence as adults); progressive degeneration was age
dependent after eclosion (SI Fig. 8). (D) HD flies were treated with vehicle (0.1% DMSO), rotenone, or sodium butyrate (NaB). Sodium butyrate (positive control)
increased the number of visible rhabdomeres. The average number of rhabdomeres per ommatidium was calculated at 9 days posteclosion and is shown as a
distribution. (See SI Fig. 8 for a dose–response experiment for rotenone.) Error bars represent one SE. *, The significant differences in the number of rhabdomeres
between vehicle- and compound-treated animals were based on Student’s t test (P  0.05).
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Fig. 3. Mitochondrial inhibitors suppress caspase 3 and 7 activation without
decreasing ATP levels. (A) Time course of cell death rescue by oligomycin
(Oligo). N548 mutant cells were treated with DMSO or oligomycin (1 M) and
analyzed by trypan blue viability assay. A total of 1,000 cells were counted per
time point. The data are means  SD of one experiment performed in
triplicate. (B) Caspase (casp) 3 and 7 activation in serum-deprived cells treated
with DMSO (D) or oligomycin (left gels) and rotenone (Rot) (right gels) was
assayed by Western blotting. Tubulin was the loading control. (C) Cells were
treated with different mitochondrial inhibitors or DMSO, and total ATP levels
were assayed after 8 h in Sdm by using a luminescence-based assay (see
Materials and Methods). ATP levels were normalized to cell number and
expressed relative to untreated cells at 0 h, set as 100% in all experiments. All
experiments were performed in triplicate, and the data are shown as means
SD. The horizontal bar shows ATP levels in untreated controls. (D) Time course
of ATP levels in DMSO and oligomycin-treated mutant cells. The data are
means  SD of an experiment that was performed in triplicate and is repre-
sentative of three independent experiments. The data were normalized to
ATP levels of DMSO-treated cells at 0.1 h that were arbitrarily set as a 100%.









mechanisms. Next, we tested whether activating ERK or AKT
independently could rescue cell death. We used two growth
factors, insulin-like growth factor 1 (IGF-1) and EGF-1 which
are known activators of AKT and ERK, respectively (31, 32). As
expected, IGF-1 caused a sustained activation of AKT but a
transient activation of ERK (Fig. 5 A andD). In contrast, EGF-1
treatment caused rapid (15 min) and sustained (10 h) activa-
tion of ERK and a transient, but lesser, activation of AKT (Fig.
5 B and E). Cells treated with IGF-1 showed a slight rescue
(5% increased viability), whereas EGF-1 increased viability by
10% (Fig. 5C). The rescue correlated with a small decrease in
caspase 3 activity (Fig. 5 D and E). However, the rescue by
growth factors was less than that by rotenone, which increased
viability by 30% and substantially inhibited caspase 3 and 7
activation (Figs. 1B and 5 D and E). Because the rescue by these
growth factors individually was less than that by rotenone, we
tested whether a combination of IGF-1 and EGF-1 would
recapitulate the rescue by rotenone. Together, IGF-1 and EGF-1
increased viability by 15% (Fig. 5C), suggesting an additive effect
that was half as effective as rotenone (Fig. 1B). These results
suggest that approximately half of the protective effect of
rotenone can be explained by activation of ERK and AKT, with
the ERK pathway being the major contributor to the rescue.
Discussion
By using a high-throughput screen, we discovered that small
molecule inhibitors of metabolism (mitochondrial and glycolytic
function) suppressed cell death in a striatal cell culture model of
HD. Furthermore, several of these inhibitors were also efficacious
in C. elegans and Drosophila HD models (SI Table 1 and Fig. 2),
suggesting that this approach targets a conservedmechanismofHD
toxicity. The role of energy metabolism in HD is controversial.
Several studies implicate deficient energy production in HD patho-
physiology; these data have been reviewed elsewhere (1, 33).
However, data exist that are not readily explained by this hypoth-
esis. First, several studies in HD animal models and patients show
no changes or even higher metabolic rates and/or mitochondrial
function compared with controls (34–38). Second, HD transgenic
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Fig. 4. Rotenone specifically activates ERK and AKT. (A) N548 mutant cells were treated with DMSO or rotenone, and AKT and ERK activations were determined
by Western blotting by using phospho-specific antibodies against serine 473 AKT, threonine 308 AKT, or threonine 202/tyrosine 204 ERK. Levels of total AKT,
ERK, and tubulin served as controls. (B) The specificity of ERK activation was confirmed by testing for activation of distinct kinase pathways. Phospho-ERK served
as a positive control. (C) Cells were treated with increasing concentrations of rotenone, and ERK/AKT activation was determined after 8 h. (D) Three independent
clonal cell lines expressing the N548 amino acid N-terminal fragment of mutant htt were treated with 10 M rotenone (Rot), and ERK/AKT activation was
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Fig. 5. Growth factors activate ERK and AKT and rescue cell death. ERK and AKT activations after treatment with IGF-1 (90 ng/ml) (A) and EGF-1 (5 ng/ml) (B)
in Sdm were assayed by Western blotting. (C) N548 mutant cells were treated with EGF-1 or IGF-1 alone or in combination, and cell viability was assayed after
2 days in Sdm by trypan blue dye exclusion assay. The results are the averages SD of one representative experiment. IGF-1 was used at one concentration (90
ng/ml); lower concentrations were ineffective, and higher concentrations did not further enhance viability. (D and E) N548 mutant cells were treated with DMSO,
rotenone (Rot), or IGF-1 (90 ng/ml) (D) or EGF-1 (5 ng/ml) (E) in Sdm, and activation of AKT, ERK, and cleaved caspase 3 and 7 levels were monitored by Western
blotting. Tubulin served as a loading control.
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mice are more resistant to a mitochondrial complex II inhibitor
(3-NP) than WT mice (39). Third, caloric restriction decreases
energymetabolism (40, 41) and yet alleviates disease progression in
HD mouse models (42). Finally, a recent study has identified
multiple metabolic changes in HD patients that suggest a procata-
bolic phenotype (43). Together with our results, these data indicate
that decreased energy metabolism may not be critical for the HD
phenotype and that a more complex interplay likely exists among
mutant htt, energy metabolism, and disease pathology.
Themechanism by which thesemetabolic inhibitors rescue cell
death does not involve a decrease in cellular ATP levels (Fig. 3C)
but involves caspase inhibition and activation of prosurvival
signaling (Figs. 3B and 5 C–E). Caspase activation is implicated
in HD pathology because caspase inhibition shows therapeutic
value in mouse HD models (44). N548 mutant cell death is also
caspase dependent because serum deprivation activates caspases
and a broad-spectrum caspase inhibitor suppresses cell death (4).
Metabolic inhibitors prevented ‘‘effector’’ caspase 3 and 7
activation (Fig. 3B), indicating that caspase inhibition by meta-
bolic inhibitors is relevant to their protective effect. Further-
more, these inhibitors activated ERK and AKT; both of these
enhance survival in diverse models (32). Activation of ERK and
AKT by the growth factors IGF-1 and EGF-1 (32, 45) rescued
cell death (Fig. 5C) and could partially explain the rescue of cell
death by metabolic inhibitors in our cell culture model.
We investigated themechanismbywhich themetabolic inhibitors
activate ERK and AKT. Diverse inhibitors of metabolic function
such as electron transport (rotenone), glycolysis (NaF), and ATP
synthetase (oligomycin) activated ERK andAKT in our cell culture
model. These results indicate that the prosurvival response is not
limited to ETC inhibition or due to off-target effects of these
compounds but is likely triggered by common metabolic effects of
these compounds. We excluded potential mechanisms, such as
changes inATP, reactive oxygen species, NADH levels (21, 22), and
mitochondrial respiration (Fig. 3 and SI Figs. 10 and 12), in
triggering prosurvival signaling or rescuing cell death. Although
mitochondria are involved primarily in energy metabolism and
apoptosis (46), a role for mitochondria in sensing cellular environ-
ment and conveying signals to other cell compartments is emerging
(47). Understanding the mode of prosurvival signal activation in
this cell culture model could reveal conserved links between
metabolism and cell survival signaling.
Altered growth factor signaling has been implicated in HD
pathology; inhibition of EGF-1 and IGF-1 signaling is reported in
HD models and patients (25, 26, 48). Conversely, activation of
growth factor signaling protects cells from mutant htt toxicity (24,
27). Although extracellular administration of growth factors can
activate these pathways, this approach is not feasible in brain tissue
of whole animals. Our study reveals a novel means of activating
ERK/AKT by using small molecules that could be exploited for
therapeutic benefit in HD and possibly other neurodegenerative
disorders. Of the active compounds, NaF and 2,4-dinitrophenol
have a history of clinical use and can cross the blood–brain barrier
(9, 49–51). These compounds are candidates for testing whether
this approach would be efficacious in mouse HD models.
Materials and Methods
Cell Culture. N548 mutant cells were maintained as described
previously (4). Cell death was induced by a change to 0.5%
FCS-containing medium (serum-deprived medium) and by incu-
bating cells at 39°C. Glucose-free DMEM (catalog no. 90-113-PB;
CellGro, Herndon, VA) was used for certain experiments.
Antibodies, Chemicals, and Growth Factors. All chemicals were
obtained from Sigma (St. Louis, MO), except IGF-1 (catalog no.
RU020; Cell Sciences, Canton, MA) and EGF-1 (PMG0062;
Invitrogen, Carlsbad, CA). Phosphoserine 473, phosphothreo-
nine 308 AKT, phospho-ERK, phospho-JAK2, phospho-NF-B
(p65 subunit), phosphoglycogen synthase kinase  /, phospho-
p38MAPK, AKT, and ERK antibodies were from Cell Signaling
Technology (Beverly, MA). Mitochondrial complex II and IV
antibodies were from Molecular Probes (Carlsbad, CA). Anti-
bodies were used at the dilutions suggested by the suppliers.
Other antibodies used have been previously described (4). The
National Institute of Neurological Disorders and Stroke custom
collection of 1,040 compounds was fromMicrosource Discovery,
Inc. (Gaylordsville, CT); and U0126 and MEK1 inhibitor (52,
53), AKT inhibitor VIII, and phosphatidylinositol 3-kinase
inhibitor LY294002 (54) were from Calbiochem (La Jolla, CA).
Western Blotting. Cells were incubated with the compounds or
vehicle (0.1% DMSO) in low serum or in 10% serum-containing
media. Cells were harvested, and Western blotting was per-
formed as described previously (4).
Cell Viability Assays. Cell viability was assayed by using the calcein
acetoxymethyl ester assay (Molecular Probes) as previously
described (4). Trypan blue cell viability was performed on N548
mutant cells by using an automated trypan blue (0.4%) dye-
exclusion assay (Vi-Cell 1.01; Beckman Coulter, Fullerton, CA)
(4). At least 200 cells were counted per sample, and the
percentage of trypan blue negative (viable) cells was calculated.
ATP Assay. Cells were plated at 105 cells per 60-mm tissue culture
dish and, after various treatments, were lysed in 200 l of lysis
buffer; ATP levels were measured by using a luminescence-based
assay as suggested by the manufacturer (catalog no. K254-200;
Biovision, Mountain View, CA). ATP controls were included to
ensure linearity of assay. The light signal (integration, 12 s) was
measured in a luminometer (Lumat LB9501; Berthold, Nashua,
NH), and luminescence was normalized to cell number. The
normalization based on protein content (protein assay reagent;
Bio-Rad, Hercules, CA) was similar to that based on cell number.
Reactive Oxygen Species Assay. The assay kit was used according
to the instructions of the manufacturer (catalog no. D-399;
Molecular Probes). In brief, 10 M H2DCFDA dye (2,7-
dichlorodihydrofluorescein diacetate) was added to 1,500 cells in
a 384-well plate, and fluorescence (excitation, 490 nm; emission,
535 nm) was measured by using a plate reader (VICTOR3;
PerkinElmer, Waltham, MA).
C. elegans Neuronal Survival Assay. The C. elegans assay has been
described previously (4, 55). In brief, L1 pqe-1;Htn-Q150 animals
were incubated at 15°C in liquid S media with a food source (E.
coli, OP50 strain) containing either a compound or DMSO
(1.5%). GFP fluorescence in bilateral ASH sensory neurons was
examined by using a fluorescence microscope (excitation, 485
nm; emission, 535 nm). One hundred neurons were scored in
50 animals. For the starvation assay, L1-arrested animals were
obtained by continued absence of food because C. elegans larvae
do not initiate growth under starvation (55). These experiments
were conducted at 25°C.
Drug Testing in Drosophila. The Drosophila HD strain (8534) was
obtained from the Bloomington Drosophila stock center and has
been described previously (14). Animals were maintained on
standard fly food at room temperature. Drugs were mixed in the
food every 2 days, and flies were fed on the food for the duration
of the experiment at 25°C. The rhabdomere number was assessed
by the pseudopupil technique (14). Equal numbers of males and
females were included in the control (DMSO) and drug-treated
samples. Eight to 10 animals were scored for each treatment, and
35 ommatidia were scored per animal. All scoring was performed
in a blinded manner, and significance was calculated by Student’s
t test.
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